Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-671 in Hospitalized Adults with COVID-19
NCT04464460Phase 1Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2020
- Primary completion
- Oct 2020
- Modality
- Antibody Fragments, Peptides, Fc-Fusion Proteins
01
Overview
Phase 1, randomised, double-blind trial of SB26 in coronavirus disease 2019 (COVID-19) (2 cohorts), sponsored by Takeda. Primary endpoints: Treatment-emergent Adverse Events, Markedly Abnormal Laboratory Values and 6 more. Planned start Sep 2020; status: withdrawn.
02
Drugs
SB26
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04464460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04464460.